Disease area hub
Oncology clinical trial failures
Review 7,871 stopped oncology clinical trials, including failure signals, sponsors, phases, and stop reasons from ClinicalTrials.gov records.
This page groups real ClinicalTrials.gov-derived stopped trial records. The strongest added signal is the stop-reason classification: 581 of these records are likely biological failure signals, while the rest may reflect operational, strategic, regulatory, funding, enrollment, or unclear stop reasons.
Dominant stop reasons
- OPERATIONAL
- 4,175
- OTHER/UNKNOWN
- 3,099
- EFFICACY/FUTILITY
- 304
- SAFETY
- 277
- REGULATORY
- 16
Notable sponsors
- M.D. Anderson Cancer Center
- 326
- National Cancer Institute (NCI)
- 311
- Novartis Pharmaceuticals
- 138
- Hoffmann-La Roche
- 97
- Washington University School of Medicine
- 91
Related phases
- Phase I
- 3,457
- Phase II
- 3,272
- Phase III
- 583
- Unknown
- 232
- Early Phase I
- 203
Crawlable stopped-trial records
Open ExploreShowing up to 100 representative records from this slice. Each link opens the trial detail page with source attribution and stop-reason context.
Phase I Non-CNS Tumor trial by Genmab. Stop reason: EFFICACY/FUTILITY.
After reviewing all available data from Part 1 of the trial, the Sponsor has decided not to proceed to Part 2 (randomized Phase 2) of the trial due to lack of efficacy
Phase III Anatomic Stage 0 Breast Cancer AJCC v8 trial by Alliance for Clinical Trials in Oncology. Stop reason: OTHER/UNKNOWN.
Amending protocol to increase sample size
Phase I Borderline Resectable Pancreatic Adenocarcinoma trial by University of Utah. Stop reason: OPERATIONAL.
Closed due to slow accrual
Phase II Lung Adenocarcinoma trial by National Cancer Institute (NCI). Stop reason: OTHER/UNKNOWN.
End of Initial Phase of Multi-phase protocol
Phase II Advanced Biliary Tract Cancer(BTC) trial by National Health Research Institutes, Taiwan. Stop reason: OPERATIONAL.
The study was terminated due to administrative reasons following the cancellation of collaboration between the involved parties.
Phase I Non-Small Cell Lung Cancer trial by National Cancer Institute (NCI). Stop reason: OPERATIONAL.
Revisions to eligibility/design being made prior to enrollment of first participants.
Phase II Diffuse Large B-Cell Lymphoma trial by Genmab. Stop reason: OTHER/UNKNOWN.
The study was terminated because sufficient data had been collected to meet the objectives of the development program. No new or unexpected safety findings were identified, and the decision to terminate was not related to participant safety.
Phase III Eyelid Squamous Cell Carcinoma trial by National Cancer Institute (NCI). Stop reason: OTHER/UNKNOWN.
Other - Other
Phase I Advanced Solid Tumor trial by Selecxine. Stop reason: OPERATIONAL.
Business decision
Phase I Multiple Myeloma trial by National Cancer Institute (NCI). Stop reason: OPERATIONAL.
Administrative hold pending non-safety related changes to the study design.
Phase II Glioma trial by National Cancer Institute (NCI). Stop reason: OTHER/UNKNOWN.
Study on hold pending possible updates with the team.
Phase I Metastatic Pancreatic Ductal Adenocarcinoma trial by Fred Hutchinson Cancer Center. Stop reason: OPERATIONAL.
Study terminated due to end of funding.
Phase I Recurrent Plasma Cell Myeloma trial by City of Hope Medical Center. Stop reason: OPERATIONAL.
Slow/Low Accrual
Phase I Acute Lymphoblastic Leukemia trial by City of Hope Medical Center. Stop reason: OPERATIONAL.
Accrual goal
Phase I Recurrent Acute Myeloid Leukemia trial by City of Hope Medical Center. Stop reason: EFFICACY/FUTILITY.
Pending Interim Analysis
Phase I Pancreatic Cancer trial by M.D. Anderson Cancer Center. Stop reason: OPERATIONAL.
PI Request
Phase I Advanced Colorectal Carcinoma trial by University of California, Davis. Stop reason: EFFICACY/FUTILITY.
For internal interim analysis
Phase I Cutaneous Melanoma trial by Seagen, a wholly owned subsidiary of Pfizer. Stop reason: OPERATIONAL.
The trial was terminated for strategic reasons. The decision was not based on any safety concerns.
Phase II Mucinous Adenocarcinoma of the Rectum trial by University of Southern California. Stop reason: OPERATIONAL.
Insufficient Accrual
Phase I HER2-positive Breast Cancer trial by University of Alabama at Birmingham. Stop reason: OPERATIONAL.
Unable to recruit for this study.
Phase I Prostate Cancer trial by Washington University School of Medicine. Stop reason: OPERATIONAL.
Low accrual
Phase II Hodgkin Lymphoma trial by Ranjana Advani. Stop reason: OTHER/UNKNOWN.
Discontinuation of magrolimab development
Phase I Glioma, Malignant trial by Northwestern University. Stop reason: SAFETY.
Safety issues
Phase II Uterine Leiomyosarcoma trial by M.D. Anderson Cancer Center. Stop reason: OPERATIONAL.
PI Request
Phase II Non-Small Cell Lung Cancer (NSCLC) trial by University Health Network, Toronto. Stop reason: OTHER/UNKNOWN.
Study Terminated Prior to trial activation, due to changes in SOC of the treatment
Early Phase I Epidural Spinal Tumors trial by Wake Forest University Health Sciences. Stop reason: OPERATIONAL.
Low accruals
Phase I Rectal Neoplasms trial by University of Iowa. Stop reason: SAFETY.
Toxicity in phase 1
Phase I Metastatic Castration-resistant Prostate Cancer trial by University of Utah. Stop reason: OTHER/UNKNOWN.
DSMC Safety Analysis
Phase I Solid Tumor, Adult trial by Virginia Commonwealth University. Stop reason: OTHER/UNKNOWN.
Pending amendment approval
Phase I Advanced Adenocarcinoma trial by University of California, Davis. Stop reason: SAFETY.
Drugs unavailable
Phase I Prostatic Neoplasms trial by Eli Lilly and Company. Stop reason: EFFICACY/FUTILITY.
The study was terminated early as related study I3Y-MC-JPCM (NCT03706365) did not meet its primary endpoint.
Phase I Lymphoma, Non-Hodgkin trial by Bristol-Myers Squibb. Stop reason: OTHER/UNKNOWN.
No stop-reason text available in the compact dataset.
Phase I Prostatic Neoplasms trial by National Cancer Institute (NCI). Stop reason: OPERATIONAL.
Slow/insufficient accrual
Phase I Acute Myeloid Leukemia trial by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Stop reason: OTHER/UNKNOWN.
Upon analysis of the first 7 participants accrued, it was determined that this combination treatment is not efficacious as treatment for patients with relapsed or refractory AML
Phase I Cutaneous Squamous Cell Carcinoma (CSCC) trial by Ankyra Therapeutics, Inc. Stop reason: OTHER/UNKNOWN.
Strategic realignment
Phase I Anatomic Stage III Breast Cancer AJCC v8 trial by National Cancer Institute (NCI). Stop reason: OTHER/UNKNOWN.
Other - DLT assessment and phase 2 dose determination
Phase III Soft Tissue Sarcoma trial by Polaris Group. Stop reason: OTHER/UNKNOWN.
Lack of Efficacy, no safety concern.
Phase III Metastatic Breast Cancer trial by SOLTI Breast Cancer Research Group. Stop reason: OPERATIONAL.
The study was prematurely halted because enrollment was significantly delayed compared with the original projections due to the evolving therapeutic landscape.
Phase II Advanced Head and Neck Squamous Cell Carcinoma trial by NRG Oncology. Stop reason: OTHER/UNKNOWN.
End of Initial Phase of Multi-phase protocol; closed for protocol specified analysis
Phase I Metastatic Castration-Resistant Prostate Carcinoma trial by National Cancer Institute (NCI). Stop reason: OPERATIONAL.
Other - To assess the study's feasibility.
Phase I Lymphocyte B CD22 Positive Acute Lymphoblastic Leukemia trial by Nantes University Hospital. Stop reason: OTHER/UNKNOWN.
No stop-reason text available in the compact dataset.
Phase II Colorectal Cancer trial by University of Southampton. Stop reason: OPERATIONAL.
funding withdrawal
Phase III Endometrial Carcinoma trial by National Cancer Institute (NCI). Stop reason: OTHER/UNKNOWN.
Other - Revisions to ICF
Phase III Recurrent Uterine Corpus Sarcoma trial by National Cancer Institute (NCI). Stop reason: EFFICACY/FUTILITY.
The study was targeted to accrue 130 patients, but closed early for futility.
Phase I Carcinoma, Non-Small-Cell Lung trial by Seagen, a wholly owned subsidiary of Pfizer. Stop reason: OPERATIONAL.
The trial was terminated for strategic reasons. The decision was not based on any safety concerns
Phase II Prostate Cancer trial by Ivan de Kouchkovsky, MD. Stop reason: OPERATIONAL.
Due to funding
Phase I Pancreatic Cancer Metastatic trial by HonorHealth Research Institute. Stop reason: EFFICACY/FUTILITY.
The study was terminated early per the recommendation of the Data and Safety Monitoring Board (DSMB) after a planned interim analysis met pre-specified criteria for futility.
Phase II Locally Advanced Malignant Solid Neoplasm trial by National Cancer Institute (NCI). Stop reason: OPERATIONAL.
Other - study has reached accrual goal for analysis
Phase I Solid Tumors trial by Boehringer Ingelheim. Stop reason: OPERATIONAL.
Sponsor decision
Phase I Ovarian Cancer trial by Novartis Pharmaceuticals. Stop reason: OPERATIONAL.
Study termination based on sponsor decision due to lack of tolerability observed with \[177Lu\]Lu-EVS459
Phase III Breast Carcinoma trial by National Cancer Institute (NCI). Stop reason: OPERATIONAL.
Closed early due to slow accrual
Phase I Lung Cancer trial by Shenzhen Geno-Immune Medical Institute. Stop reason: OTHER/UNKNOWN.
combine with NCT03356808
Phase II Prostate Cancer trial by University Hospital, Bordeaux. Stop reason: OTHER/UNKNOWN.
target number of patients not reached
Phase I Advanced Solid Tumors trial by Debiopharm International SA. Stop reason: OPERATIONAL.
This trial was concluded for strategic reasons.
Phase I Advanced HR+/HER2- Breast Cancer trial by Novartis Pharmaceuticals. Stop reason: OPERATIONAL.
Business decision
Phase I Solid Tumors trial by Amgen. Stop reason: OPERATIONAL.
Sponsor Decision
Phase I Advanced Hepatocellular Carcinoma trial by Roswell Park Cancer Institute. Stop reason: OTHER/UNKNOWN.
awaiting agreement with Sponsor
Phase III NSCLC (Advanced Non-small Cell Lung Cancer) trial by ImmunityBio, Inc.. Stop reason: OPERATIONAL.
Sponsor decision
Unknown Prostate Cancer trial by University Hospital, Montpellier. Stop reason: OTHER/UNKNOWN.
Flaw in the analytical technique
Phase I Head and Neck Cancer trial by Case Comprehensive Cancer Center. Stop reason: OTHER/UNKNOWN.
PI leaving the institution
Phase I Desmoplastic Small Round Cell Tumor trial by National Cancer Institute (NCI). Stop reason: OPERATIONAL.
Other - Stage 1 has met accrual
Phase II Metastatic Pancreatic Adenocarcinoma trial by Mayo Clinic. Stop reason: OPERATIONAL.
Low/slow accrual
Phase II Multiple Myeloma (MM) trial by Regeneron Pharmaceuticals. Stop reason: OPERATIONAL.
Sponsor Decision
Phase I Cancer trial by Biond Biologics. Stop reason: OTHER/UNKNOWN.
Study terminated due to strategic considerations
Phase I Advanced Solid Tumor trial by Cullinan Therapeutics Inc.. Stop reason: OPERATIONAL.
Company decision
Phase I HER2-positive Breast Cancer trial by H. Lee Moffitt Cancer Center and Research Institute. Stop reason: OTHER/UNKNOWN.
Wait for the DLT period with our current patient and will not be enrolling any more.
Phase I HER2-positive Breast Cancer trial by Day One Biopharmaceuticals, Inc.. Stop reason: OTHER/UNKNOWN.
Development discontinued.
Phase I Ovarian Cancer trial by NewLink Genetics Corporation. Stop reason: OPERATIONAL.
Company decision
Phase I Breast Cancer trial by M.D. Anderson Cancer Center. Stop reason: SAFETY.
Toxicity and Lack of Efficacy
Phase I SCLC trial by Y-mAbs Therapeutics. Stop reason: OTHER/UNKNOWN.
Decision by Sponsor
Phase I Metastatic Malignant Solid Neoplasm trial by National Cancer Institute (NCI). Stop reason: OTHER/UNKNOWN.
Other - Correlative sample analysis.
Phase I Advanced Malignant Solid Neoplasm trial by National Cancer Institute (NCI). Stop reason: OTHER/UNKNOWN.
Other - Amendment needed to add new dose level.
Phase I Brain Metastases trial by Medical College of Wisconsin. Stop reason: OPERATIONAL.
Study never started.
Phase III Melanoma trial by Centre Hospitalier Universitaire de Nice. Stop reason: OTHER/UNKNOWN.
Rupture du traitement
Phase II Locally Recurrent Skin Squamous Cell Carcinoma trial by National Cancer Institute (NCI). Stop reason: OTHER/UNKNOWN.
Other - safety run-in for initial cohort of participants
Phase III Non-small Cell Lung Cancer trial by Novartis Pharmaceuticals. Stop reason: OTHER/UNKNOWN.
Results of primary analysis showed addition of canakinumab to combination treatment did not improve tumor response or overall survival; the decision to stop the trial was not due to safety concerns
Phase I Metastatic Colorectal Adenocarcinoma trial by National Cancer Institute (NCI). Stop reason: OTHER/UNKNOWN.
Other - Pending amendment.
Phase I Relapsed/Refractory Multiple Myeloma trial by Second Affiliated Hospital of Xi'an Jiaotong University. Stop reason: OTHER/UNKNOWN.
Achieved the proof of concept
Phase II Chronic Myelomonocytic Leukemia trial by M.D. Anderson Cancer Center. Stop reason: OPERATIONAL.
PI request
Phase I Cancer trial by Baptist Health South Florida. Stop reason: OPERATIONAL.
Funding
Phase II Colorectal Carcinoma trial by National Cancer Institute (NCI). Stop reason: OTHER/UNKNOWN.
New information received
Phase II Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma trial by David Bond, MD. Stop reason: OPERATIONAL.
sponsor decision
Phase I Solid Tumor trial by Servier Bio-Innovation LLC. Stop reason: OPERATIONAL.
Sponsor decision to terminate during Phase 1
Phase II Pain Management trial by Wake Forest University Health Sciences. Stop reason: OPERATIONAL.
Study initially suspended following an audit and need of amendment to address deficiencies. PI requested to terminate due to lack of support.
Phase II Metastatic Nasopharyngeal Carcinoma trial by National Cancer Institute (NCI). Stop reason: OTHER/UNKNOWN.
Scheduled Interim Monitoring
Phase II Breast Cancer trial by Mayo Clinic. Stop reason: OPERATIONAL.
slow accrual; insufficient funding to continue to accrue
Phase II Melanoma trial by Regeneron Pharmaceuticals. Stop reason: OPERATIONAL.
Business Decision
Phase II Recurrent B-Cell Non-Hodgkin Lymphoma trial by University of Washington. Stop reason: OPERATIONAL.
The trial closed early due to slow accrual.
Phase I Stage III Pancreatic Cancer AJCC v8 trial by City of Hope Medical Center. Stop reason: OPERATIONAL.
Accrual Goal met
Phase I Cutaneous T Cell Lymphoma trial by University of Alabama at Birmingham. Stop reason: OTHER/UNKNOWN.
IRB audit
Phase II Metastatic Cancer trial by M.D. Anderson Cancer Center. Stop reason: OPERATIONAL.
PI request
Phase II Stage IV Colorectal Cancer Positive for BRAF V600E Mutation trial by Northwestern University. Stop reason: OPERATIONAL.
The study was closed due to accrual.
Phase II Soft Tissue Sarcoma trial by Sun Yat-sen University. Stop reason: OTHER/UNKNOWN.
The study was terminated due to initiation of a new clinical trial with an updated study design.
Phase II Carcinoma, Non-Small-Cell Lung trial by NeoImmuneTech. Stop reason: OPERATIONAL.
sponsor decision (not for safety)
Phase I Advanced Solid Tumor trial by SpringWorks Therapeutics, Inc.. Stop reason: OTHER/UNKNOWN.
Lack of tolerability of BGB-3245 (Brimarafenib) when given in combination with Mirdametinib
Phase II Estrogen Receptor Positive Breast Cancer trial by University of Pennsylvania. Stop reason: OTHER/UNKNOWN.
No stop-reason text available in the compact dataset.
Phase I Acute Myeloid Leukemia trial by Northwestern University. Stop reason: OTHER/UNKNOWN.
Premature withdrawal of investigational product per study sponsor.
Phase II Multiple Myeloma trial by National Cancer Institute (NCI). Stop reason: OTHER/UNKNOWN.
Scheduled Interim Monitoring
Phase I Multiple Myeloma trial by Thomas Martin, MD. Stop reason: OTHER/UNKNOWN.
Safety Review
Phase II Cutaneous Melanoma trial by Genmab. Stop reason: OPERATIONAL.
Genmab has decided to discontinue further clinical development of acasunlimab following strategic portfolio prioritization. The decision was not related to safety concerns.